Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity.

NCT04752774 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT04752774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04752774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity.
Lead sponsor
Ipsen
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 29, 2021
Completion date
March 30, 2029
Enrollment
240 (estimated)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

spasticity